It is worth noting that there is a certain similarity in pathological manifestations between IgAN with IgA-κ deposits and proliferative glomerulonephritis with monoclonal IgA deposits (IgA-PGNMID), but the latter has a risk of progressing to hematological malignancies, a worse prognosis, and requires targeted B cell/plasma cell therapy. The gene discussed is CD79A; the disease is proliferative glomerulonephritis.